← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › VASODILATORS USED IN CARDIAC DISEASES › Other vasodilators used in cardiac diseases
prenylamine
C01DX02
Adult Dosing
- Angina pectoris: 60 mg to 120 mg orally daily, divided into 2-3 doses, titrated based on clinical response up to a maximum of 180 mg daily.
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established.
Indications
- Prophylaxis of chronic stable angina pectoris
Mechanism of Action
- Calcium channel blocker with slow-channel blocking properties and sympatholytic effects.
- Depletes myocardial catecholamine stores and inhibits calcium influx into vascular smooth muscle and myocardium.
- Reduces myocardial oxygen demand and induces coronary vasodilation.
Contraindications
- Hypersensitivity to prenylamine
- Pre-existing QT prolongation or history of torsades de pointes
- Severe bradycardia
- Second- or third-degree AV block without a pacemaker
- Decompensated heart failure
- Concomitant use of other drugs that prolong the QT interval or cause hypokalemia
Adverse Reactions
- Torsades de pointes and fatal ventricular arrhythmias
- QT interval prolongation
- Dizziness, headache, fatigue
- Nausea, gastrointestinal upset
- Weight gain
- Hypotension
Drug Interactions
- Class IA and Class III antiarrhythmic drugs (increased risk of severe QT prolongation and arrhythmias)
- QT-prolonging agents such as antipsychotics, tricyclic antidepressants, and certain macrolide antibiotics
- Diuretics (risk of hypokalemia, further increasing arrhythmia risk)
- Beta-blockers and non-dihydropyridine calcium channel blockers (additive negative inotropic and chronotropic effects)
Curated Content: Needs Vetting Before Put to Clinical Use